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Epithelial–mesenchymal transition (also known as EMT) is a fundamental mechanism occur-
ring during embryonic development and tissue differentiation, being also crucial for cancer
progression. Actually, the EMT program contributes to the dissemination of cancer cells
from solid tumors and to the formation of micro-metastasis that subsequently develop
into clinically detectable metastases. Besides being a process that is defined by the pro-
gressive loss of epithelial cell characteristics and the acquisition of mesenchymal features,
EMT has also been implicated in therapy resistance, immune escape, and maintenance
of cancer stem cell properties, such as self-renewal capacity. However, the majority of
the studies usually neglect the progressive alterations occurring during intermediate EMT
states, which imply a range of phenotypic cellular heterogeneity that can potentially gener-
ate more metastable and plastic tumor cells. In fact, few studies have tried to identify these
transitory states, partly due to the current lack of a detailed understanding of EMT, as well
as of reliable readouts for its progression. Herein, a brief review of evidences is presented,
showing that P-cadherin expression, which has been already identified as a breast cancer
stem cell marker and invasive promoter, is probably able to identify an intermediate EMT
state associated with a metastable phenotype.This hypothesis is based on our own work,
as well as on the results described by others, which suggest the use of P-cadherin as a
promising EMT marker, clearly functioning as an important clinical prognostic factor and
putative therapeutic target in breast carcinogenesis.
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EMT: EPITHELIAL TO MESENCHYMAL TRANSITION
Epithelial–mesenchymal transition (EMT) is a highly regulated
transdifferentiation cellular program, by which static and polar-
ized epithelial cells convert to an invasive and motile mesenchymal
morphology. During the EMT process, there is the progressive
loss of epithelial characteristics and the acquisition of mesenchy-
mal features, which, in a cancer context, leads to the development
of cells that are chemoresistant, able to escape to immune cells
and with stem cell properties. Moreover, this phenotypic trans-
formation gives cancer cells the ability to invade locally, to resist
apoptosis, and to metastasize (1–4). Interestingly, the phenotypic
plasticity afforded by EMT is revealed by the occurrence of the
reverse process, a mesenchymal–epithelial transition (or MET)
(5–7), which involves the conversion of mesenchymal cells to an
epithelial cell phenotype.
EMT STATES
Epithelial–mesenchymal transition is a multistep program that
involves a series of changes by which epithelial cells lose their
epithelial characteristics and acquire properties that are typical
of mesenchymal cells. One of the earliest events during EMT
involves the decrease in proteins from tight and adherent junc-
tions (8). Epithelial-like cells exhibit an organized apical–basal
polarity maintained by the precise arrangement of actin fila-
ments and adhesive structures, such as tight junctions, adherens
junctions, and desmosomes (9). Specialized adhesive molecules,
such as cadherins, integrins, and other cell-surface proteins, are
essential for the maintenance of the epithelial phenotype by sta-
bilizing cell–cell contacts. Thus, a decreased expression of these
proteins complex triggers redistribution of key molecules at the
cell surface, disruption of the polarity complex, and cytoskeletal
reorganization (10). Following loss of junctional complexes and
downregulation of E-Cadherin (epithelial cadherin), β−catenin is
no longer sequestered in the cytoplasm and translocates to the
nucleus to activate β-catenin responsive genes. In the nucleus,
a transcriptional shift is observed, where several transcription
factors suppress epithelial markers and activate mesenchymal
genes, promoting a mesenchymal-like phenotype (11). At this
stage, cytoskeletal proteins are upregulated, as is the deposition
of the extracellular matrix (ECM) components. All these alter-
ations stimulate integrin signaling and promote the formation of
focal adhesion complexes, leading in this way to an increase in cell
motility and invasion capacity.
Conversely to epithelial cell phenotype, mesenchymal cells
are characterized by a unique spindle morphology defined by a
front-back-end polarity and enhanced invasive potential (12, 13).
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However, not all cells undergo a complete EMT; instead, most
cells undergo partial EMT, an intermediate state in which cells
retain some cell–cell adhesion characteristic of epithelial cells,
but gain some migratory ability, that is a feature of mesenchy-
mal cells (1). This means that cancer cells in this transient EMT
phenotype are endowed with special properties, such as collective
cell migration and invasion. Moreover, the transient phenotypic
changes during EMT have been also associated with the acquisition
of stem-like properties. Actually, the intermediate EMT stage has
been coined as the metastable phenotype (14), since it describes
the simultaneous existence of both epithelial and mesenchymal
characteristics, being of great importance for the understanding
of the major cellular changes associated with the progression of
the EMT program.
Curiously, the identification of EMT transient stages has been
neglected, although it is thought to be more prevalent than the
pure mesenchymal cell morphology. In fact, it has been accepted
by several authors that this hybrid phenotype, reflecting epithelial–
mesenchymal plasticity, should be included in these intermediate
states of EMT, implying a range of phenotypic cellular heterogene-
ity that can generate more plastic and metastable tumor cells (1).
Interestingly, the metastatic capacity of these cells is consistent with
the expression of stem cell markers in colorectal cells undergoing
EMT (15), suggesting that such plasticity may be found in progen-
itor cells in various organs. This plasticity can explain why it is so
rare to observe cells undergoing EMT during cancer progression,
and also that the acquisition of mesenchymal characteristics may
be transitory, undergoing a reverse process during the last stages
of tumorigenesis (6).
Due to the tremendous difficulty in capturing cells in the inter-
mediate states of EMT (16), most studies have been focused in
finding biomarkers that identify the non-invasive full epithelial
state, as well as the aggressive, motile, and invasive mesenchymal
state.
CLASSICAL EMT MARKERS
The conversion of epithelial-like cells into mesenchymal-like cells
requires alterations in cellular morphology, adhesion, and migra-
tory capacity. The different degrees of EMT can occur in carcino-
mas, being the alterations found in the expression of molecular
markers used to assess the EMT status (17).
At the molecular level, the EMT transition is characterized
by a series of coordinated changes including downregulation of
epithelial markers (e.g., cytokeratin 8, 18, 19, E-cadherin, claudins,
occludins) and upregulation of mesenchymal markers (e.g.,
vimentin, N-cadherin) (18), what results in numerous phenotypic
changes, such as the loss of cell–cell adhesion and cell polarity,
and the acquisition of migratory and invasive properties (3, 15).
The cell intermediate filament status changes from a keratin-rich
network, which connects to adherens junctions and hemidesmo-
somes, to a vimentin-rich network connecting to focal adhesions.
The loss of functional E-cadherin containing junctions with
the concomitant upregulation of N-cadherin (19, 20) is termed
cadherin switch and is a hallmark of the EMT process. This
switch has been already reported for carcinomas in the esophagus,
prostate, cervix, and ovary (20–23), being associated with tumor
progression and metastatic disease.
Epithelial–mesenchymal transition process is also particularly
associated with the expression of zinc-finger transcription factors
Snail (SNAI1) and Slug (SNAI2), as well as of ZEB1 (zinc-finger
E-box-binding homeobox 1), ZEB2, FoxC2 (forkhead box protein
C2), and TWIST (24, 25). Moreover, several evidences show that
the expression of the intermediate filament protein vimentin can
be upregulated by different EMT transcription factors in a direct or
indirect way (26–30). Both mesenchymal proteins, vimentin and
fibronectin, contribute to changes in cytoskeletal architecture and
migratory potential of cancer cells (27). All these alterations cause
cells to change to a mesenchymal morphology and to a functional
change toward migration, invasion, and resistance to apoptosis.
Concerning the transient/metastable phenotype, few specific
markers have been proposed, due to the lack of studies evalu-
ating the progressive and transitory states of EMT, as well as of
reliable readouts for its progression. Knowing that, there is the
need to find markers to identify this metastable phenotype, which
will be crucial to understand how to clinically prevent metastasis
and to give mechanistic insights to be translated into therapeutic
opportunities.
P-CADHERIN: A PROMISING EMT MARKER
Cell–cell adhesion, mediated by E-cadherin at adherens junctions,
is essential for the maintenance of epithelial tissue architecture and
homeostasis. Altered expression and/or function of E-cadherin
play a major role in the acquisition of cell invasive properties
and in the induction of EMT, as well as tumor progression. Dur-
ing EMT, epithelial adherens junctions are dynamically regulated,
which trigger signaling pathways and alterations in the organiza-
tion of the actin cytoskeleton that are involved in the induction
of cell motility. In fact, the well-known cadherins switch, namely
the loss of E-cadherin and the gain of N-cadherin, is described as
being characteristic of EMT and is associated with tumor cell inva-
sion. However, there are examples of highly aggressive and inva-
sive tumors, like basal-like breast carcinomas, where E-cadherin
expression is rarely lost, and N-cadherin is hardly overexpressed
(31). In contrast, these tumors usually overexpress other classical
cadherin, named P-cadherin, mainly in a wild-type E-cadherin
context, which intriguingly has never been linked to the EMT
process. However, since it has been already proven that P-cadherin
is able to interfere with epithelial cell–cell adhesion and to pro-
mote cancer cell invasion and metastasis (32), it is our belief that
P-cadherin can be also used as a new EMT marker, mainly to iden-
tify an intermediate and transient EMT state associated with a
metastable phenotype.
P-CADHERIN IS A FACTOR OF POOR PROGNOSIS IN BREAST CANCER
The role of P-cadherin in breast carcinogenesis has been exten-
sively studied in the last few years. Presently, it is known that
this protein is de novo expressed in near 30–40% of invasive
breast carcinomas, being reported as a valuable prognostic fac-
tor in this disease. P-cadherin-positive carcinomas are significantly
associated with tumors of high histological grade, with short-term
overall and disease-free survival, as well as with distant and loco-
regional relapse-free interval (31, 33–35). P-cadherin expression
still shows a strong correlation with invasion of the vascular and
soft tissues (36). Moreover, the overexpression of this protein has
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also been positively associated with well-established markers and
biological parameters associated to poor prognosis in breast can-
cer, such as epidermal growth factor receptor (EGFR), cytokeratin
5 (CK5), vimentin, p53 and HER2, high proliferation rates (MIB-
1), mitotic index, and decreased cell differentiation (31, 33, 34,
37). P-cadherin expression was also inversely related with age at
diagnosis, hormonal receptors (ER and PgR) and Bcl-2 expression
(31, 33–35).
Interestingly, P-cadherin is a marker of triple-negative (which
means negative for ER, PgR, and HER2) basal-like breast carci-
nomas, which comprise a heterogeneous group of tumors that
accounts for up to 15% of all breast cancer cases (31). These tumors
are highly aggressive, affect younger patients, are more prevalent in
African-American women, and often are present as interval can-
cers. Histologically, the majority of basal-like breast cancers are
IDC-NST (invasive ductal carcinomas of no special type), high
histological grade, and characterized by exceptionally high mitotic
indices, the presence of central necrotic or fibrotic zones, pushing
borders, conspicuous lymphocytic infiltrate, and typical/atypical
medullary features (38). As the name indicates, these tumors
express genes and proteins usually found in basal/myoepithelial
cells of the normal breast, including high-molecular-weight cytok-
eratins (5/6, 14, and 17), P-cadherin, caveolins 1 and 2, nestin, αB
crystallin, CD109, and EGFR (39). Since, until today, these tumors
do not harbor any therapeutic target usually used to treat breast
cancer patients, all these proteins, including P-cadherin, can be
putative therapeutic options to be targeted.
P-CADHERIN AND CANCER CELL INVASION
In contrast to E-cadherin, which is an important invasion sup-
pressor protein, it has been shown that P-cadherin behaves as an
invasion promoter in several cancer models, including breast can-
cer. It has been often reported that P-cadherin induces increased
tumor cell motility and invasiveness when aberrantly overex-
pressed (40–46). Our group has demonstrated that one of the
mechanisms underlying the invasive capacity of P-cadherin over-
expression in breast cancer cells is mediated by the secretion of
matrix metalloproteases (MMPs), which degrade the ECM during
invasion (44, 45) and cleave P-cadherin extracellular domain to
produce a soluble P-cadherin fragment (sP-cad). Interestingly, we
have demonstrated that this fragment has pro-invasive effects in
non-invasive breast cancer cells (45) (Figure 1). Accordingly, it was
demonstrated a significant increased shedding of sP-cad in nipple
aspirate fluids from women with breast cancer, when compared
with healthy subjects or with women with pre-cancer conditions,
suggesting its release via proteolytic processing in cancer cells (47).
Furthermore, the invasive phenotype mediated by P-cadherin
was seemingly dependent on the concomitant expression of wild-
type E-cadherin: in cell models where P-cadherin showed an
invasion promoter function, E-cadherin was also expressed (44,
46, 48, 49); contrarily, in models, which only express P-cadherin,
this protein was described as an invasion suppressor (50–52). This
dual functional role of P-cadherin was recently explained by the
induction of an aggressive biological cell behavior in cells co-
expressing both cadherins compared to cells just expressing one of
each cadherin. Indeed, we have found that P-cadherin expression
disrupts the normal invasive suppressor function of E-cadherin
FIGURE 1 | Hallmarks of P-cadherin function in breast cancer cells.
P-cadherin overexpressing cells acquire features that give them an
advantage to survive in a hostile environment leading to an invasive and
tumorigenic phenotype of breast cancer cells. P-cadherin expression affects
cell–cell adhesion, since it disrupts the normal suppressor function of
E-cadherin, by decreasing the interaction between E-cadherin and
intracellular catenins. Overexpression of this protein in breast cancer cells
promotes an increase in cell migration and cell invasion, being able to
provoke the secretion of pro-invasive factors, such as MMP1 and MMP2,
which then lead to P-cadherin ectodomain cleavage (sP-cad) that also has
pro-invasive activity by itself. Moreover, P-cadherin expression mediates
cancer stem cell properties, conferring resistance to x-ray-induced cell
death and being related with a hypoxic, glycolytic, and acid-resistant
phenotype in breast cancer cells.
(32) by destabilizing the normal cadherin/catenin complex (53).
The induced-delocalization of β-catenin and p120-catenin from
the membrane to the cytoplasm alters the actin cytoskeleton poly-
merization, and promotes cell migration and motility, as well as an
increased invasive and tumorigenic potential (32, 46) (Figure 1).
P-CADHERIN AS A CANCER STEM CELL MARKER
Breast carcinomas, as well as other solid tumors, contain a small
population of cancer cells that have the ability to self-renew and
to be tumorigenic, generating all the distinct cancer cells present
within the tumor. These cells were called breast cancer stem cells
(CSCs), which are the apex of a hierarchy that is comparable to
the one established in normal tissues (54). Breast CSCs share a
large amount of properties with mammary stem cells, namely the
ability to resist to standard cancer therapies, such as radiation
and chemotherapy, allowing them to survive and to cause tumor
recurrence and metastasis (55–58). Targeting breast CSCs, in com-
bination with current therapies, is the forthcoming goal in breast
cancer treatment.
In this context, we have demonstrated that P-cadherin expres-
sion is able to identify basal-like breast cancer cells with stem cell
properties. Using breast cancer cell lines and primary tumors, we
showed that P-cadherin was directly associated with the expression
of the breast stem markers CD44, CD49f, and aldehyde dehydro-
genase 1 (ALDH1) in the basal-like molecular subtype. Moreover,
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P-cadherin-enriched cancer cell populations comprised increased
in vitro mammosphere-forming efficiency, as well as increased
tumorigenicity. Additionally, the expression of this adhesion mol-
ecule still conferred resistance to x-ray-induced cell death, sus-
taining a role for this molecule in another stem cell property (59)
(Figure 1).
Importantly, we found that P-cadherin expression was associ-
ated with stem-/progenitor-like phenotypes of the breast, includ-
ing the luminal progenitor population, CD49f+CD24+. Accord-
ingly, Nassour et al. recently demonstrated that the expression of
Slug, P-cadherin, and CD49f has a role in the growth dynam-
ics of a subpopulation of cycling progenitor basal cap and duct
cells during mammary morphogenesis (60). Moreover, we were
able to establish that there is a crosstalk between the expres-
sion of P-cadherin and CD49f (α6 integrin). Actually, we have
demonstrated that P-cadherin regulates the laminin receptor α6β4
integrin-signaling pathway, which activation explains the stem cell
and invasive properties induced by P-cadherin to breast cancer
cells (61).
Cancer stem cells are also usually described as hypoxia-
resistant, presenting a preponderant glycolytic metabolism. These
characteristics are also found enriched in basal-like breast carcino-
mas, which show increased expression of cancer stem cell markers
(62). Interestingly, we demonstrated that cancer cell populations
harboring high levels of P-cadherin were the same exhibiting more
GLUT1 and CAIX expression. Moreover, its silencing significantly
decreased the mammosphere-forming efficiency in the same range
as the silencing of HIF-1α, CAIX, or GLUT1, substantiating that
all these markers are being expressed by the same breast cancer
stem cell population (63) (Figure 1).
P-CADHERIN AS A POTENTIAL THERAPEUTIC TARGET
All the knowledge that was acquired concerning P-cadherin
expression in cancer supported the development of anti-P-
cadherin therapeutic strategies. A humanized monoclonal anti-
body (PF-03732010) was developed to antagonize P-cadherin-
regulated cell–cell adhesion and the associated signaling pathway.
Actually, a study using this antibody confirmed the role of P-
cadherin as a molecule involved in cell invasion, as well as in metas-
tization. The authors observed that PF-03732010 treated cells and
tumors showed disrupted P-cadherin signaling and resulted in
anti-tumorigenic and anti-metastatic activity (64).
Based on these results and on our own data, we hypothesize
that P-cadherin could be a promising marker of the metastable
and intermediate EMT phenotype (Figure 2). The rationale for
this hypothesis relies on the fact that P-cadherin expression dis-
turbs epithelial cell–cell adhesion and promotes the acquisition
of a more undifferentiated cell phenotype, acquiring these cells
an intermediate phenotypic state between epithelial and mes-
enchymal morphology. Additionally, P-cadherin overexpressing
cells show increased therapy resistance, stem cell properties, and a
more aggressive and invasive behavior. Finally, P-cadherin expres-
sion is a factor of poor prognosis in breast cancer, being associated
to tumors with high metastatic potential. Thus, all these character-
istics points to a transient EMT state, with cancer cells harboring
an increased plasticity and metastability.
This premise seems to be corroborated by preliminary data that
we have recently produced, where a three-protein EMT signature
has been applied to a series of 500 invasive breast carcinomas,
using the expression of two classical EMT markers, E-cadherin
and vimentin, combined with P-cadherin expression. Our results
FIGURE 2 | Proposed model of P-cadherin expression in EMT
progression. Schematic representation adapted from Schmitt et al. (54) of
the different types of breast cancer in what concerns cancer stem cells
proteins (CD24, CD44, CD49f, and ALDH1), EMT markers, and P-cadherin
expression during EMT progression. A decrease of epithelial proteins with a
concomitant increase in mesenchymal markers is observed during the
transition from an epithelial to a mesenchymal phenotype. During this
process, we hypothesize that P-cadherin expression is in very low levels in
both full epithelial and full mesenchymal states; however, an increased
expression can be seen in the metastable and intermediate states of EMT.
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show that P-cadherin identifies an intermediate state between the
epithelial and the mesenchymal phenotypes, associating to a poor
prognosis in breast cancer patients, but also with the expression
of breast cancer stem cell markers. Although this data need fur-
ther validation, both in independent breast cancer series and by
in vitro and in vivo functional assays, our future aim is to definitely
prove the crucial role of P-cadherin in identifying the EMT “inter-
mediate/metastable” phenotype. Proving this hypothesis, we will
clarify the role of P-cadherin in the EMT process, identifying it as
a putative EMT marker and supporting the use of anti-P-cadherin
therapeutics to metastatic breast cancer.
REFERENCES
1. Klymkowsky MW, Savagner P. Epithelial-mesenchymal transition: a cancer
researcher’s conceptual friend and foe. Am J Pathol (2009) 174:1588–93.
doi:10.2353/ajpath.2009.080545
2. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states:
acquisition of malignant and stem cell traits. Nat Rev Cancer (2009) 9:265–73.
doi:10.1038/nrc2620
3. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transi-
tions in development and disease. Cell (2009) 139:871–90. doi:10.1016/j.cell.
2009.11.007
4. Yilmaz M, Christofori G. Emt, the cytoskeleton, and cancer cell invasion. Cancer
Metastasis Rev (2009) 28:15–33. doi:10.1007/s10555-008-9169-0
5. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated
observation of breast tumor subtypes in independent gene expression data sets.
Proc Natl Acad Sci USA (2003) 100:8418–23. doi:10.1073/pnas.0932692100
6. Brabletz T. Emt and met in metastasis: where are the cancer stem cells? Cancer
Cell (2012) 22:699–701. doi:10.1016/j.ccr.2012.11.009
7. Carstens JL, Lovisa S, Kalluri R. Microenvironment-dependent cues trigger
mirna-regulated feedback loop to facilitate the emt/met switch. J Clin Invest
(2014) 124:1458–60. doi:10.1172/JCI75239
8. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dys-
function promote tumor progression?Oncogene (2008) 27:6920–9. doi:10.1038/
onc.2008.343
9. Han SP, Yap AS. The cytoskeleton and classical cadherin adhesions. Subcell
Biochem (2012) 60:111–35. doi:10.1007/978-94-007-4186-7_6
10. Brieher WM, Yap AS. Cadherin junctions and their cytoskeleton(s). Curr Opin
Cell Biol (2013) 25:39–46. doi:10.1016/j.ceb.2012.10.010
11. Azmi AS. Unveiling the role of nuclear transport in epithelial-to-mesenchymal
transition. Curr Cancer Drug Targets (2013) 13:906–14. doi:10.2174/
15680096113136660096
12. Hay ED. The mesenchymal cell, its role in the embryo, and the remarkable
signaling mechanisms that create it. Dev Dyn (2005) 233:706–20. doi:10.1002/
dvdy.20345
13. Zavadil J, Haley J, Kalluri R, Muthuswamy SK, Thompson E. Epithelial-
mesenchymal transition. Cancer Res (2008) 68:9574–7. doi:10.1158/0008-5472.
CAN-08-2316
14. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal tran-
sition: new insights in signaling, development, and disease. J Cell Biol (2006)
172:973–81. doi:10.1083/jcb.200601018
15. Ksiazkiewicz M, Markiewicz A, Zaczek AJ. Epithelial-mesenchymal transition:
a hallmark in metastasis formation linking circulating tumor cells and cancer
stem cells. Pathobiology (2012) 79:195–208. doi:10.1159/000337106
16. Krasnapolski MA, Todaro LB, de Kier Joffe EB. Is the epithelial-to-mesenchymal
transition clinically relevant for the cancer patient? Curr Pharm Biotechnol
(2011) 12:1891–9. doi:10.2174/138920111798377021
17. Chaw SY, Majeed AA, Dalley AJ, Chan A, Stein S, Farah CS. Epithelial to
mesenchymal transition (emt) biomarkers – e-cadherin, beta-catenin, apc and
vimentin – in oral squamous cell carcinogenesis and transformation. Oral Oncol
(2012) 48:997–1006. doi:10.1016/j.oraloncology.2012.05.011
18. Markiewicz A, Ahrends T, Welnicka-Jaskiewicz M, Seroczynska B, Skokowski
J, Jaskiewicz J, et al. Expression of epithelial to mesenchymal transition-related
markers in lymph node metastases as a surrogate for primary tumor metasta-
tic potential in breast cancer. J Transl Med (2012) 10:226. doi:10.1186/1479-
5876-10-226
19. Li G, Herlyn M. Dynamics of intercellular communication during melanoma
development. Mol Med Today (2000) 6:163–9. doi:10.1016/S1357-4310(00)
01692-0
20. Tomita K, van Bokhoven A, van Leenders GJ, Ruijter ET, Jansen CF, Bussemakers
MJ, et al. Cadherin switching in human prostate cancer progression. Cancer Res
(2000) 60:3650–4.
21. Bailey T, Biddlestone L, Shepherd N, Barr H, Warner P, Jankowski J.
Altered cadherin and catenin complexes in the Barrett’s esophagus-dysplasia-
adenocarcinoma sequence: correlation with disease progression and dedifferen-
tiation. Am J Pathol (1998) 152:135–44.
22. de Boer CJ, van Dorst E, van Krieken H, Jansen-van Rhijn CM, Warnaar SO,
Fleuren GJ, et al. Changing roles of cadherins and catenins during progression
of squamous intraepithelial lesions in the uterine cervix. Am J Pathol (1999)
155:505–15. doi:10.1016/S0002-9440(10)65146-2
23. Patel IS, Madan P, Getsios S, Bertrand MA, MacCalman CD. Cadherin switch-
ing in ovarian cancer progression. Int J Cancer (2003) 106:172–7. doi:10.1002/
ijc.11086
24. Lim J, Thiery JP. Epithelial-mesenchymal transitions: insights from develop-
ment. Development (2012) 139:3471–86. doi:10.1242/dev.071209
25. Chu PY, Hu FW, Yu CC, Tsai LL, Yu CH, Wu BC, et al. Epithelial-mesenchymal
transition transcription factor zeb1/zeb2 co-expression predicts poor prognosis
and maintains tumor-initiating properties in head and neck cancer. Oral Oncol
(2013) 49:34–41. doi:10.1016/j.oraloncology.2012.07.012
26. Guo J,Fu Z,Wei J,Lu W,Feng J,Zhang S. Prrx1 promotes epithelial-mesenchymal
transition through the wnt/beta-catenin pathway in gastric cancer. Med Oncol
(2015) 32:393. doi:10.1007/s12032-014-0393-x
27. Ivaska J. Vimentin: central hub in emt induction? Small GTPases (2011) 2:51–3.
doi:10.4161/sgtp.2.1.15114
28. Ivaska J, Heino J. Cooperation between integrins and growth factor recep-
tors in signaling and endocytosis. Annu Rev Cell Dev Biol (2011) 27:291–320.
doi:10.1146/annurev-cellbio-092910-154017
29. Kaufhold S, Bonavida B. Central role of snail1 in the regulation of emt and
resistance in cancer: a target for therapeutic intervention. J Exp Clin Cancer Res
(2014) 33:62. doi:10.1186/s13046-014-0062-0
30. Liu AN, Zhu ZH, Chang SJ, Hang XS. Twist expression associated with the
epithelial-mesenchymal transition in gastric cancer. Mol Cell Biochem (2012)
367:195–203. doi:10.1007/s11010-012-1333-8
31. Paredes J, Albergaria A, Oliveira JT, Jeronimo C, Milanezi F, Schmitt FC. P-
cadherin overexpression is an indicator of clinical outcome in invasive breast
carcinomas and is associated with cdh3 promoter hypomethylation. Clin Cancer
Res (2005) 11:5869–77. doi:10.1158/1078-0432.CCR-05-0059
32. Ribeiro AS, Sousa B, Carreto L, Mendes N, Nobre AR, Ricardo S, et al.
P-cadherin functional role is dependent on e-cadherin cellular context: a
proof of concept using the breast cancer model. J Pathol (2013) 229:705–18.
doi:10.1002/path.4143
33. Gamallo C, Moreno-Bueno G, Sarrio D, Calero F, Hardisson D, Palacios J. The
prognostic significance of p-cadherin in infiltrating ductal breast carcinoma.
Mod Pathol (2001) 14:650–4. doi:10.1038/modpathol.3880367
34. Peralta Soler A, Knudsen KA, Salazar H, Han AC, Keshgegian AA. P-
cadherin expression in breast carcinoma indicates poor survival. Cancer
(1999) 86:1263–72. doi:10.1002/(SICI)1097-0142(19991001)86:7<1263::AID-
CNCR23>3.0.CO;2-2
35. Turashvili G, McKinney SE, Goktepe O, Leung SC, Huntsman DG, Gel-
mon KA, et al. P-cadherin expression as a prognostic biomarker in a 3992
case tissue microarray series of breast cancer. Mod Pathol (2011) 24:64–81.
doi:10.1038/modpathol.2010.189
36. Liu N,Yu Q, Liu TJ, Gebreamlak EP, Wang SL, Zhang RJ, et al. P-cadherin expres-
sion and basal-like subtype in breast cancers. Med Oncol (2012) 29:2606–12.
doi:10.1007/s12032-012-0218-8
37. Sousa B, Paredes J, Milanezi F, Lopes N, Martins D, Dufloth R, et al. P-cadherin,
vimentin and ck14 for identification of basal-like phenotype in breast carcino-
mas: an immunohistochemical study. Histol Histopathol (2010) 25:963–74.
38. Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, et al. Basal-like
and triple-negative breast cancers: a critical review with an emphasis on the
implications for pathologists and oncologists. Mod Pathol (2011) 24:157–67.
doi:10.1038/modpathol.2010.200
39. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al.
Molecular portraits of human breast tumours. Nature (2000) 406:747–52.
doi:10.1038/35021093
www.frontiersin.org January 2015 | Volume 4 | Article 371 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ribeiro and Paredes P-cadherin and EMT
40. Cheung LW, Leung PC, Wong AS. Cadherin switching and activation of p120
catenin signaling are mediators of gonadotropin-releasing hormone to pro-
mote tumor cell migration and invasion in ovarian cancer. Oncogene (2010)
29:2427–40. doi:10.1038/onc.2009.523
41. Kumper S, Ridley AJ. P120ctn and p-cadherin but not e-cadherin regulate cell
motility and invasion of du145 prostate cancer cells. PLoS One (2010) 5:e11801.
doi:10.1371/journal.pone.0011801
42. Mandeville JA, Silva Neto B, Vanni AJ, Smith GL, Rieger-Christ KM, Zeheb
R, et al. P-cadherin as a prognostic indicator and a modulator of migra-
tory behaviour in bladder carcinoma cells. BJU Int (2008) 102:1707–14.
doi:10.1111/j.1464-410X.2008.08115.x
43. Paredes J, Correia AL, Ribeiro AS, Albergaria A, Milanezi F, Schmitt FC. P-
cadherin expression in breast cancer: a review. Breast Cancer Res (2007) 9:214.
doi:10.1186/bcr1774
44. Paredes J, Stove C, Stove V, Milanezi F, Van Marck V, Derycke L, et al. P-
cadherin is up-regulated by the antiestrogen ici 182,780 and promotes invasion
of human breast cancer cells. Cancer Res (2004) 64:8309–17. doi:10.1158/0008-
5472.CAN-04-0795
45. Ribeiro AS, Albergaria A, Sousa B, Correia AL, Bracke M, Seruca R, et al.
Extracellular cleavage and shedding of p-cadherin: a mechanism underlying
the invasive behaviour of breast cancer cells. Oncogene (2010) 29:392–402.
doi:10.1038/onc.2009.338
46. Taniuchi K, Nakagawa H, Hosokawa M, Nakamura T, Eguchi H, Ohigashi H,
et al. Overexpressed p-cadherin/cdh3 promotes motility of pancreatic cancer
cells by interacting with p120ctn and activating rho-family gtpases. Cancer Res
(2005) 65:3092–9. doi:10.1158/0008.5472.CAN-04-3646
47. Mannello F, Tonti GA, Medda V, Pederzoli A, Sauter ER. Increased shedding
of soluble fragments of p-cadherin in nipple aspirate fluids from women
with breast cancer. Cancer Sci (2008) 99:2160–9. doi:10.1111/j.1349-7006.2008.
00921.x
48. Ben Hamida A, Labidi IS, Mrad K, Charafe-Jauffret E, Ben Arab S, Esterni B,
et al. Markers of subtypes in inflammatory breast cancer studied by immuno-
histochemistry: prominent expression of p-cadherin. BMC Cancer (2008) 8:28.
doi:10.1186/1471-2407-8-28
49. Cheung LW, Mak AS, Cheung AN, Ngan HY, Leung PC, Wong AS. P-cadherin
cooperates with insulin-like growth factor-1 receptor to promote metastatic sig-
naling of gonadotropin-releasing hormone in ovarian cancer via p120 catenin.
Oncogene (2011) 30:2964–74. doi:10.1038/onc.2011.7
50. Bauer K, Dowejko A, Bosserhoff AK, Reichert TE, Bauer RJ. P-cadherin induces
an epithelial-like phenotype in oral squamous cell carcinoma by gsk-3beta-
mediated snail phosphorylation. Carcinogenesis (2009) 30:1781–8. doi:10.1093/
carcin/bgp175
51. Sarrio D, Palacios J, Hergueta-Redondo M, Gomez-Lopez G, Cano A, Moreno-
Bueno G. Functional characterization of e- and p-cadherin in invasive breast
cancer cells. BMC Cancer (2009) 9:74. doi:10.1186/1471-2407-9-74
52. Van Marck V, Stove C, Van Den Bossche K, Stove V, Paredes J, Vander Haeghen
Y, et al. P-cadherin promotes cell-cell adhesion and counteracts invasion in
human melanoma. Cancer Res (2005) 65:8774–83. doi:10.1158/0008-5472.
CAN-04-4414
53. Paredes J, Correia AL, Ribeiro AS, Milanezi F, Cameselle-Teijeiro J, Schmitt FC.
Breast carcinomas that co-express e- and p-cadherin are associated with p120-
catenin cytoplasmic localisation and poor patient survival. J Clin Pathol (2008)
61:856–62. doi:10.1136/jcp.2007.052704
54. Schmitt F, Ricardo S, Vieira AF, Dionisio MR, Paredes J. Cancer stem cell mark-
ers in breast neoplasias: their relevance and distribution in distinct molecular
subtypes. Virchows Arch (2012) 460:545–53. doi:10.1007/s00428-012-1237-8
55. Visvader JE. Cells of origin in cancer. Nature (2011) 469:314–22. doi:10.1038/
nature09781
56. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-
mesenchymal transition generates cells with properties of stem cells. Cell (2008)
133:704–15. doi:10.1016/j.cell.2008.03.027
57. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of
breast cancer stem cells through epithelial-mesenchymal transition. PLoS One
(2008) 3:e2888. doi:10.1371/journal.pone.0002888
58. Ablett MP, Singh JK, Clarke RB. Stem cells in breast tumours: are they ready for
the clinic? Eur J Cancer (2012) 48:2104–16. doi:10.1016/j.ejca.2012.03.019
59. Vieira AF, Ricardo S, Ablett MP, Dionisio MR, Mendes N, Albergaria A, et al. P-
cadherin is coexpressed with cd44 and cd49f and mediates stem cell properties
in basal-like breast cancer. Stem Cells (2012) 30:854–64. doi:10.1002/stem.1075
60. Nassour M, Idoux-Gillet Y, Selmi A, Come C, Faraldo ML, Deugnier MA, et al.
Slug controls stem/progenitor cell growth dynamics during mammary gland
morphogenesis. PLoS One (2012) 7:e53498. doi:10.1371/journal.pone.0053498
61. Vieira AF, Ribeiro AS, Dionisio MR, Sousa B, Nobre AR, Albergaria A, et al. P-
cadherin signals through the laminin receptor alpha6beta4 integrin to induce
stem cell and invasive properties in basal-like breast cancer cells. Oncotarget
(2014) 5:679–92.
62. Ricardo S, Vieira AF, Gerhard R, Leitao D, Pinto R, Cameselle-Teijeiro JF,
et al. Breast cancer stem cell markers cd44, cd24 and aldh1: expression dis-
tribution within intrinsic molecular subtype. J Clin Pathol (2011) 64:937–46.
doi:10.1136/jcp.2011.090456
63. Sousa B, Ribeiro AS, Nobre AR, Lopes N, Martins D, Pinheiro C, et al. The basal
epithelial marker p-cadherin associates with breast cancer cell populations har-
boring a glycolytic and acid-resistant phenotype. BMC Cancer (2014) 14:734.
doi:10.1186/1471-2407-14-734
64. Zhang CC, Yan Z, Zhang Q, Kuszpit K, Zasadny K, Qiu M, et al. Pf-03732010:
a fully human monoclonal antibody against p-cadherin with antitumor and
antimetastatic activity. Clin Cancer Res (2010) 16:5177–88. doi:10.1158/1078-
0432.CCR-10-1343
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 22 October 2014; paper pending published: 21 November 2014; accepted: 11
December 2014; published online: 05 January 2015.
Citation: Ribeiro AS and Paredes J (2015) P-cadherin linking breast cancer stem cells
and invasion: a promising marker to identify an “intermediate/metastable” EMT state.
Front. Oncol. 4:371. doi: 10.3389/fonc.2014.00371
This article was submitted to Molecular and Cellular Oncology, a section of the journal
Frontiers in Oncology.
Copyright © 2015 Ribeiro and Paredes. This is an open-access article distributed under
the terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
Frontiers in Oncology | Molecular and Cellular Oncology January 2015 | Volume 4 | Article 371 | 6
